Fig. 2From: Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in GermanyPrevalence of at least one prescription of any (A) and specific medication (B) in the years 2009 to 2016. The curves were fitted using a cubic spline function. Panel A: vertical lines refer to the introduction of prescription restrictions issued by the Federal Joint Committee (G-BA) in the respective years. Panel B: Dexamfetamine, lisdexamfetamine and guanfacine were licensed in the years 2012, 2013 and 2016 in Germany, respectivelyBack to article page